WeTrials
Recruiting

Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)

What is this study?

This study is testing a new medication called evexomostat when taken along with standard treatments for a specific type of advanced breast cancer. Researchers want to see if this combination is safe and if it can help reduce blood sugar side effects often caused by standard therapies.

Who can participate?

This study is open to men and post-menopausal women with HR-positive, HER2-negative advanced breast cancer that has specific genetic changes in the PI3K pathway. You will also need to meet other health and medical history requirements to join.

What will happen?

Participants will receive a combination of drugs, including evexomostat and standard treatments chosen by their doctor. Your health team will closely monitor your safety, tumor response, and blood sugar levels throughout the study.

Where and when?

The study is currently recruiting patients at multiple locations in California, United States. Your care team can help you find the most convenient site for your visits.

Key Points
  • 1Tests a new drug combination for advanced breast cancer
  • 2Aims to manage and reduce blood sugar side effects
  • 3Currently recruiting patients in California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
HR+/HER2-negative Breast CancerMetastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.